Pegvisomant in combination or pegvisomant alone after failure of somatostatin analogs in acromegaly patients: an observational French ACROSTUDY cohort study

OBJECTIVE: After surgery, when somatostatin analogs (SAs) do not normalise IGF-I, pegvisomant (PEG) is indicated. Our aim was to define the medical reasons for the treatment of patients with PEG as monotherapy (M) or combined with SA, either as primary bitherapy, PB (PEG is secondarily introduced af...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Endocrine
Main Authors: Kuhn, Emmanuelle, Caron, Philippe, Delemer, Brigitte, Raingeard, Isabelle, Lefebvre, Hervé, Raverot, Gérald, Cortet-Rudelli, Christine, Desailloud, Rachel, Geffroy, Clementine, Henocque, Robin, Brault, Yves, Brue, Thierry, Chanson, Philippe
Formato: Artigo
Idioma:Inglês
Publicado em: Springer US 2020
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7835180/
https://ncbi.nlm.nih.gov/pubmed/32986202
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12020-020-02501-3
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados